Entero Therapeutics

FL - Boca RatonBiotechnology1 H-1B visas (FY2023)

Focus: Entero Therapeutics is a small-stage biotech focused on oxidative phosphorylation disruption therapies for inflammatory bowel disease and related gastrointestinal conditions. The company is headquartered in Boca Raton, Florida and operates as a pre-revenue biotech with a diversified pipeline across immunology and gastroenterology.

Immunology Gastroenterology

Profile data last refreshed Yesterday · AI intelligence enriched 2w ago

Open Jobs

About Entero Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Entero Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

10 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

Simvastatin

Celiac Disease

Phase 1

Clinical Trials (1)

NCT03011931Simvastatin Metabolism as a Test for CD Activity (IRB 15-007568]

Phase 1

Help build intelligence for Entero Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Portfolio diversification across validated mechanisms: Niclosamide (COVID, ulcerative colitis), Latiglutenase (celiac disease), and MS1819 (pancreatic insufficiency) span multiple indications with unmet needs
Early-stage opportunity to shape drug development: 9 total trials (8 Phase 2, 2 Phase 1) offer hands-on involvement in clinical program design and execution
Emerging science in novel target space: Focus on oxidative phosphorylation disruption represents differentiated mechanism with potential first-mover advantage in IBD

Watch Out For

Zero hiring activity and financial opacity: No active job openings and missing data on funding, revenue, and cash position signal potential capital constraints or dormant operations
No marketed products or revenue: Pre-revenue status with earliest Phase 2 programs 2-3+ years from potential approval creates high cash burn risk without visibility into funding runway
Minimal published science and no Phase 3 data: Zero publications and absence of late-stage programs reduce likelihood of near-term clinical validation or exit catalyst

Generated by Claude from Entero Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Niclosamide

Ulcerative Colitis

Phase 1/2

Clinical Trials (1)

NCT03521232A Study of Niclosamide Enemas in Subjects With Active Ulcerative Proctitis or Ulcerative Proctosigmoiditis

Phase 1/2

MS1819

Exocrine Pancreatic Insufficiency (EPI)

Phase 2

Clinical Trials (1)

NCT03746483OPTION: A Trial to Assess the Safety & Efficacy of MS1819 in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Phase 2